EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Spruce Biosciences's enterprise value is $-45.32 Mil.
Spruce Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $10.13 Mil. Therefore, Spruce Biosciences's EV-to-Revenue for today is -4.48.
The historical rank and industry rank for Spruce Biosciences's EV-to-Revenue or its related term are showing as below:
SPRB'
s EV-to-Revenue Range Over the Past 10 Years
Min: -25.83 Med: -5.85 Max: 13.1
Current: -4.47
During the past 6 years, the highest EV-to-Revenue of Spruce Biosciences was 13.10. The lowest was -25.83. And the median was -5.85.
SPRB's EV-to-Revenue is ranked better than 95.78% of 1043
companies
in the Biotechnology industry
Industry Median: 8.03
vs SPRB: -4.47
The historical data trend for Spruce Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spruce Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Spruce Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's EV-to-Revenue falls into.
Spruce Biosciences's current Enterprise Value is $-45.32 Mil.
Spruce Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences's share price for today is $0.75.
Spruce Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Spruce Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Spruce Biosciences (Spruce Biosciences) Business Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRB has been successfully added to your 